Oxford Biomedica plc (OXB.L), a cell and gene therapy contract development and manufacturing organization, on Tuesday said it has signed a new multi-year commercial supply agreement with Bristol-Myers Squibb Co. (BMY) to manufacture and supply lentiviral vectors for BMS' CAR-T programmes. Under the...
Swiss drug major Novartis AG (NVS) reported Wednesday lower profit in its fourth quarter, despite sales growth. Further, the company lifted dividend, and issued fiscal 2026 outlook, expecting lower core operating income and higher net sales. In the fourth quarter, net income dropped 15 percent to...
Novartis AG (NVS) released earnings for fourth quarter that Drops, from last year The company's earnings came in at $2.404 billion, or $1.26 per share. This compares with $2.820 billion, or $1.42 per share, last year. Excluding items, Novartis AG reported adjusted earnings of $3.889 billion or...
Veradermics, Incorporated (MANE), a late clinical-stage biopharmaceutical company, announced the pricing of its upsized initial public offering of 15.08 million shares at $17 per share. In addition, Veradermics has granted the underwriters a 30-day option to purchase up to an additional 2.26 million...
British drug major GSK plc (GSK, GSK.L) reported Wednesday higher profit and revenues in its fourth quarter, and issued fiscal 2026 outlook, expecting increase in core profit and turnover. Further, the firm reaffirmed its long-term outlooks, projecting 2031 sales outlook of more than 40 billion pounds. Looking...
GSK plc (GSK) revealed earnings for its fourth quarter that Increased, from last year The company's bottom line came in at GBP727 million, or GBP0.156 per share. This compares with GBP501 million, or GBP0.100 per share, last year. The company's revenue for the period rose 6.2% to GBP8.618 billion...
Pfizer Inc. (PFE) on Tuesday announced positive topline results from the Phase 2b VESPER-3 study evaluating monthly maintenance dosing of its ultra-long-acting, injectable GLP-1 receptor agonist PF'3944 in adults with obesity or overweight without type 2 diabetes. The study's dual objectives were...
Danish drug maker Novo Nordisk A/S (NVO, NOVOB.CO, NOV.DE) announced late Monday headline results from REIMAGINE 2 trial, in which CagriSema demonstrated both superior HbA1c reduction and weight loss at week 68 versus semaglutide, across all tested doses in adults with type 2 diabetes. CagriSema is...
Venglustat
Sanofi (SNY, SAN.PA) reported that the LEAP2MONO phase 3 study demonstrated that venglustat met the primary and three out of four key secondary endpoints in adults and pediatric patients with neurological manifestations of type 3 Gaucher disease. Venglustat demonstrated superiority versus enzyme replacement...
Relay Therapeutics' zovegalisib receives FDA Breakthrough Therapy designation for PIK3CA-mutant HR+/HER2- advanced breast cancer, sending pre-market shares up over 3%.
The FDA approved 46 novel drugs in 2025, with 70% receiving approval in the United States before any other country, according to a report from the Center for Drug Evaluation and Research (CDER). Several drugs are scheduled for FDA review this February. Will they pass the regulatory muster, or will they be sent back to the drawing board?
March 19, 2025 09:33 ET This week's video covers several intriguing topics: a merger of two pharma companies with a troubled past to create a global, diversified pharmaceuticals leader; a novel therapy in the works that could change the treatment landscape of Hunter syndrome, if approved; and a partnership to unlock Petrelintide’s potential for obesity treatment. Additionally, we explore the CDC's investigation into a potential link between vaccines and autism, amid the growing number of autism diagnoses.
HOOKIPA Pharma Inc. (HOOK), a clinical-stage biopharmaceutical company, announced the sale of its immunooncology assets, Eseba-vec, also known as HB-200 and HB-700 development programs, to NeoTrail Therapeutics, Inc. HOOKIPA develops immunotherapeutics for cancer and other infectious diseases using...
A fast-growing measles outbreak in South Carolina, now the largest in recent U.S. history, has broken the record in the contagious disease reported in Texas last year. South Carolina's Department of Public Health announced that the number of confirmed cases has reached 789, eclipsing the record of...
A research team from Northwestern University in the US developed a total artificial lung (TAL) system that works like human lungs by adding oxygen to the blood. The system also helps control blood flow and reduces strain on the heart. The system was developed for a man from Missouri, who was airlifted...
New research found that using generative artificial intelligence (AI) every day may be linked to a higher risk of depressive symptoms and other negative effects, especially among younger and middle-aged adults. For this, researchers reviewed nearly 1.5 million conversations with Anthropic's Claude...
The Centers for Disease Control and Prevention has announced that its Traveler-Based Genomic Surveillance program has surpassed one million voluntary participants, marking a significant milestone in the United States' ability to detect and respond to emerging public health threats at its borders. TGS...
Shares of Amylyx Pharmaceuticals Inc. (AMLX) touched a new 52-week high of $17.20 yesterday, and that represents a gain of over 50% in less than a month.